Skip to content

Nuvation Bio NUVB Warrants And Rights Outstanding

Warrants And Rights Outstanding at other companies

ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$308.19M+3,316%

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:WarrantsAndRightsOutstanding.

The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's warrants and rights outstanding.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's warrants and rights outstanding?
Nuvation Bio (NUVB) reported warrants and rights outstanding of $2.87M in Q4 2025.
How has Nuvation Bio's warrants and rights outstanding changed year-over-year?
Nuvation Bio's warrants and rights outstanding increased by 39.6% year-over-year, from $2.05M to $2.87M.
What is the long-term trend for Nuvation Bio's warrants and rights outstanding?
Over 5 years (2020 to 2025), Nuvation Bio's warrants and rights outstanding has grown at a -29.1% compound annual growth rate (CAGR), from $15.94M to $2.87M.
What does warrants and rights outstanding mean?
This represents the fair value or contractual obligation associated with outstanding warrants and rights that grant holders the option to purchase company equity. These instruments are often issued as part of financing rounds or incentive packages and can lead to future share dilution. Investors track this to assess the potential impact on earnings per share and equity structure.